Matthias H. Busch

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar, Sanne de Bruin, Matthias H. Busch et al. · The Lancet Rheumatology · 2020 · 198 citations · Full text

Clinical Infectious Disease, Covid-19 Pandemic, Immunology +7

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 131 citations · Full text

Critical Care Medicine, Clinical Infectious Disease, Anti-c5a Antibody +6

Diversity in prevalence and characteristics of ESBL/pAmpC producing E. coli in food in Germany

Annemarie Kaesbohrer, Karin Lebl, Alexandra Irrgang et al. · Veterinary Microbiology · 2019 · 121 citations · Full text

Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Frank B. Cortazar, John L. Niles, David Jayne et al. · Kidney International Reports · 2023 · 77 citations · Full text

The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Alexander P. J. Vlaar, Endry H. T. Lim, Sanne de Bruin et al. · Clinical and Translational Science · 2022 · 38 citations · Full text

Immunology, Severe Covid‐19, Pharmacotherapy +19